Plantable Health Inc. provided an update on its clinical trials which are expected to further validate Plantable's Reboot program as a clinically-proven program to optimize health, and address the epidemic of chronic disease including obesity, high cholesterol, diabetes and certain cancers. The successful conclusion of Plantable's clinical trials unlocks a significant market opportunity to address this growing market segment. Following the successful conclusion of the clinical trials, Plantable intends to establish partnership relationships with medical institutions and insurance companies, developing co-branded programs to support physicians with their patient's overall treatment.

Plantable's alternative healthcare programs seek to be prescribed by physicians as science-based, natural alternatives to insulin, statins, and weight loss drugs. Plantable's current and pipeline clinical trials are as follows: The Breast Cancer Trial at the Memorial Sloan Kettering Cancer Center based in New York, NY. This is a Phase 2 randomized control trial with Dr. Neil Iyengar as the Principal Investigator.

This trial is active and is expected to conclude by mid-2023. The Myeloma Cancer Trial at the Memorial Sloan Kettering Cancer Center in New York, NY, with Principal Investigator Dr. Urvi Shah. This trial is active and is expected to conclude by late 2022.

Prostate Cancer Trial at Weill Cornell Medical College in New York, NY and at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MA with Dr. David Nanus as the Principal Investigator. This trial is expected to commence recruitment in early 2022. Each of the clinical trials described above sets out to assess the impact of a whole food plant-based dietary intervention, as administered by Plantable, on independent cancer risks which include weight loss, the microbiome and metabolic markers including cholesterol, blood sugar and inflammation, associated with other major chronic conditions.

In all three trials, Plantable is the dietary intervention which combines Plantable's personalized behavioral coaching, with an educational lifestyle platform and the home delivery and guidance of whole food, plant-based meals to reset dietary habits associated with the overconsumption of added sugar and processed food. The clinical trials were initiated by the Company following the successful outcome of the data collected from Plantable's initial data samples (Foundational Results) collected from May 2015, October 2015 through to September 2017. The Foundational Results assessed the impact of Plantable's Reboot Program and documented that participants experienced a reduction in blood sugar (HgbA1C) by -0.91 pts, a reduction in inflammation (hsCRP) by -1.3 pts and a reduction in cholesterol (LDL) by -41 pts.

Additionally, participants on average lost 8.9 pounds and reduced their waist circumference by 2 inches in the first 28 days.